Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer.
Details
Serval ID
serval:BIB_117BC2FB7E6C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer.
Journal
Breast cancer
ISSN
1880-4233 (Electronic)
ISSN-L
1340-6868
Publication state
Published
Issued date
11/2018
Peer-reviewed
Oui
Volume
25
Number
6
Pages
698-705
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
CD44 and aldehyde dehydrogenase 1 (ALDH1) has been reputed to be cancer stem cell (CSC) markers in breast cancer. Yet, the clinicopathologic and prognostic significance of these markers remain unclear. In this study, we have investigated the expression of these markers and their relation with conventional clinicopathologic tumor characteristic including molecular subtype.
CD44 and ALDH1 expression were investigated by immunohistochemistry in a series of 157 formalin-fixed paraffin-embedded breast cancer tissues.
Overall, CD44 and ALDH1 are, respectively, detected in 33% (52 of 157) and 7% (10 of 157) of breast cancer cases. We also observed that CD44 expression was associated with histological grade (p = 0.005). For ALDH1, we found that its expression is more frequent with elderly women (> 50 years, p = 0.03). The investigation of relationship between the stem cell phenotype and breast cancer molecular subtype, revealed that CD44 and ALDH1 expression was more frequent in basal-like tumors (p = 0.005). Among the two cancer stem cell markers tested, ALDH1 showed a strong association with the basal marker EGFR (p = 0.05).
These findings suggest that CD44 and ALDH1 play a role in the clinical behavior in breast cancer and might be interesting biomarkers and therapeutic targets.
CD44 and ALDH1 expression were investigated by immunohistochemistry in a series of 157 formalin-fixed paraffin-embedded breast cancer tissues.
Overall, CD44 and ALDH1 are, respectively, detected in 33% (52 of 157) and 7% (10 of 157) of breast cancer cases. We also observed that CD44 expression was associated with histological grade (p = 0.005). For ALDH1, we found that its expression is more frequent with elderly women (> 50 years, p = 0.03). The investigation of relationship between the stem cell phenotype and breast cancer molecular subtype, revealed that CD44 and ALDH1 expression was more frequent in basal-like tumors (p = 0.005). Among the two cancer stem cell markers tested, ALDH1 showed a strong association with the basal marker EGFR (p = 0.05).
These findings suggest that CD44 and ALDH1 play a role in the clinical behavior in breast cancer and might be interesting biomarkers and therapeutic targets.
Keywords
Adult, Aged, Aged, 80 and over, Aldehyde Dehydrogenase 1 Family, Biomarkers, Tumor/analysis, Breast Neoplasms/chemistry, Breast Neoplasms/pathology, Female, Humans, Hyaluronan Receptors/analysis, Hyaluronan Receptors/physiology, Isoenzymes/analysis, Isoenzymes/physiology, Middle Aged, Neoplastic Stem Cells/chemistry, Retinal Dehydrogenase/analysis, Retinal Dehydrogenase/physiology, Aldehyde dehydrogenase 1, Basal-like, Breast cancer, CD44, Cancer stem cell
Pubmed
Web of science
Create date
17/10/2023 7:42
Last modification date
20/10/2023 6:10
Usage data
